Clinical pharmacology and therapeutics
-
Clin. Pharmacol. Ther. · Nov 2001
Randomized Controlled Trial Clinical TrialEffect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Lansoprazole is mainly metabolized by cytochrome P4502C19 (CYP2C19) in the liver. The effect of lansoprazole is assumed to be insufficient in subjects who are homozygous extensive metabolizers of CYP2C19. This study aimed to examine whether the CYP2C19 genotype status affected the acid-inhibitory effects of lansoprazole and to develop a strategy to overcome this pharmacogenetic problem. ⋯ The effect of lansoprazole on intragastric pH depended significantly on CYP2C19 genotype status. Complete acid inhibition could be achieved by the frequent administration of lansoprazole (eg, 30 mg 4 times daily) in subjects who were homozygous extensive metabolizers. A genotyping test of CYP2C19 status appears useful for prescribing an optimal dosing scheme of lansoprazole.
-
Clin. Pharmacol. Ther. · Nov 2001
Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine.
We investigated the pharmacokinetics of ketamine with special regard to enantiomer-specific differences. ⋯ These results demonstrate that R(-)-ketamine inhibits the elimination of S(+)-ketamine.